Dasatinib News and Research

RSS

Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.

Senolytic drugs rejuvenate blood stem cells in sickle cell disease

Sickle cell disease causes premature aging of blood stem cells, which scientists may be able to address with a special class of drugs, according to a new study from St. Jude Children's Research Hospital.

22 Jul 2026

Senolytic therapy delays early disc degeneration in mouse model

Targeting senescent cells with dasatinib-quercetin preserves disc structure and modulates degeneration-associated pathways in a mouse model.

25 May 2026

Targeting senescent fat cells provides new hope for ovarian cancer

Ovarian cancer is the most lethal malignancy of the female reproductive system. Due to its insidious early symptoms and the absence of specific screening modalities, approximately 70% of patients are diagnosed at an advanced stage.

13 Apr 2026

Anti-aging drug combination causes brain damage in mice

A two-drug combination frequently used in anti-aging research causes brain damage in mice, University of Connecticut researchers report in the March 16 issue of PNAS.

17 Mar 2026

Optimized costimulatory domains boost tumor killing in CAR NK cells

Researchers at the Ribeirão Preto Blood Center and the Center for Cell-Based Therapy (CTC) conducted a study using the NK-92 cell line to test new models of chimeric antigen receptors (CARs) with specific costimulatory domains, such as 2B4 and DAP12.

20 Feb 2026

A senescence-based therapeutic approach for temporal lobe epilepsy

Temporal lobe epilepsy, which results in recurring seizures and cognitive dysfunction, is associated with premature aging of brain cells.

22 Dec 2025

New in vitro platform predicts drug toxicity, improving cancer treatment safety

Overcoming acquired treatment resistance is one of the major challenges in the fight against cancer. While combination therapies hold promise, their toxicity to healthy tissue remains a major hurdle. To anticipate these risks, researchers at the University of Geneva (UNIGE) have developed in vitro models of the kidneys, liver, and heart - three organs particularly sensitive to such therapies.

16 Dec 2025

Scientists outline how organ rejuvenation strategies could solve the donor shortage

Researchers outline why organs from older donors are often discarded and identify the biological and immunological pathways that make them vulnerable to injury. They also highlight emerging rejuvenation technologies including machine perfusion, senotherapeutics, and regenerative strategies that could safely expand the donor pool.

11 Dec 2025

Immune aging drives the progression of type 2 diabetes

Type 2 diabetes (T2D) is a global metabolic epidemic driven by insulin resistance (IR), chronic inflammation, and β-cell failure.

6 Aug 2025

The vicious circle of aging and metabolic dysfunction-associated steatotic liver disease

Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) and aging are locked in a vicious circle: senescence of liver cells accelerates fat accumulation, inflammation and fibrosis, while chronic steatosis in turn hastens hepatic decline.

1 Aug 2025

Distinct subtypes of senescent skin cells identified

Senescent skin cells, often referred to as zombie cells because they have outlived their usefulness without ever quite dying, have existed in the human body as a seeming paradox, causing inflammation and promoting diseases while also helping the immune system to heal wounds.

26 Apr 2025

Senolytics offer hope for more precise Alzheimer's treatments

A new research paper was published in Aging (Aging-US) on March 29, 2025, as the cover of Volume 17, Issue 3, titled "Differential senolytic inhibition of normal versus Aβ-associated cholinesterases: implications in aging and Alzheimer's disease."

1 Apr 2025

Study identifies PDGFRA as a potential target for pediatric high-grade gliomas

Pediatric high-grade gliomas, particularly H3K27M diffuse midline gliomas (DMG), are aggressive malignant brain tumors with a poor prognosis.

26 Mar 2025

Melanoma cells use stealth strategy to survive targeted therapy

Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a promising new approach to improving treatment outcomes.

20 Mar 2025

Pilot study explores potential of senolytics in Alzheimer's prevention

A new pilot study known as STAMINA (Senolytics To Alleviate Mobility Issues and Neurological Impairments in Aging), that focused on the effects of senolytic medications, Dasatinib and Quercetin (DQ), which remove old (senescent) cells from the body, suggests that intermittent treatment may hold promise for improving cognitive function in older adults at risk of Alzheimer's disease.

26 Feb 2025

New approach to treating ependymoma with leukemia drug

Rakesh Jain PhD, Director of the E.L. Steele Laboratories for Tumor Biology at Massachusetts General Hospital and A. Werk Cook Professor of Radiation Oncology at Harvard Medical School, is senior author of a new study in PNAS, Targeting EPHB2/ABL1 Restores Anti-Tumor Immunity in Preclinical Models of Ependymoma.

23 Jan 2025

Senolytic agents show promise in mouse model of pelvic organ prolapse

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 19 on September 26, 2024, entitled, "Use of the senolytics dasatinib and quercetin for prevention of pelvic organ prolapse in a mouse animal model."

22 Oct 2024

Senolytic drugs are not a "one-size-fits-all" remedy and may benefit some older women

Drugs that selectively kill senescent cells may benefit otherwise healthy older women but are not a "one-size-fits-all" remedy, Mayo Clinic researchers have found.

2 Jul 2024

Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.

11 Dec 2023

Researchers discover way to reverse brain aging caused by COVID-19

University of Queensland researchers have found a way to reverse a cellular process triggered by COVID-19 that contributes to premature aging of the brain.

22 Nov 2023